Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22879158 | 1.00 | BCL2L1 (0.87) | BCL2L1BCL2 | |
| SCHEMBL29424547 | 1.00 | BCL2L1 (0.87) | BCL2L1BCL2 | |
| SCHEMBL30405101 | 0.99 | BCL2L1 (0.85) | BCL2L1BCL2 | |
| SCHEMBL31570836 | 0.99 | BCL2L1 (0.85) | BCL2L1BCL2 | |
| SCHEMBL25423836 | 0.93 | BCL2L1 (0.94) | BCL2L1BCL2 | |
| SCHEMBL25423839 | 0.93 | BCL2L1 (0.94) | BCL2L1BCL2 | |
| SCHEMBL554094 | 0.93 | BCL2L1 (1.00) | BCL2L1BCL2 | |
| SCHEMBL554095 | 0.93 | BCL2L1 (1.00) | BCL2L1BCL2 | |
| SCHEMBL19145119 | 0.93 | BCL2L1 (0.84) | BCL2L1BCL2 | |
| SCHEMBL30777653 | 0.93 | BCL2L1 (1.00) | BCL2L1BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220273666-A1 | NANOPARTICLE FORMULATION OF BCL-2 INHIBITOR | RECURIUM IP HOLDINGS, LLC | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273666-A1 | NANOPARTICLE FORMULATION OF BCL-2 INHIBITOR | BCL2, BCL2L2, BCL2L1 | BCL2L1 3/4885BCL2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.